
Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
Filed with NSE · · 3 pages · English

Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon